Business in the Burbs

Progenics drug approved in Australia

November

Progenics Pharmaceuticals Inc., an Eastview-based biotech company, said that its Relistor constipation drug can be sold in Australia following regulatory approval in that country.

Progenics partnered with Wyeth in 2005 to jointly develop and sell Relistor, an injectable drug designed to treat constipation caused by painkillers. It is the first commercial product for Progenics.

“Approval in Australia expands global access to this novel product which has already received approval in Canada, the U.S., European Union member states, and Iceland, Norway, Liechtenstein and Venezuela,” Chief Executive Officer Paul J. Maddon said in a written statement.

This entry was posted on Monday, November 17th, 2008 at 2:14 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.